(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 29 March 2001 (29.03.2001)

PCT

(10) International Publication Number WO 01/21811 A1

(51) International Patent Classification⁷: 15/85, A61K 31/711

C12N 15/54,

(21) International Application Number: PCT/CA00/01097

(22) International Filing Date:

21 September 2000 (21.09.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

09/401,780

22 September 1999 (22.09)1999) US

(71) Applicant (for all designated States except US): THE UNIVERSITY OF MANITOBA [CA/CA]; 753 McDermot Avenue, Winnipeg, Manitoba R3T 2N2 (CA).

(72) Inventor; and

(75) Inventor/Applicant (for US only); BRUNHAM, Robert, C. [CA/CA]; 620 West 17th Avenue, Vancouver, British Columbia V5Z 1T8 (CA).

(74) Agent: STEWART, Michael, I.; Sim & McBurney, 6th Floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA). (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DNA IMMUNIZATION AGAINST CHLAMYDIA INFECTION

(57) Abstract: Nucleic acid, including DNA, immunization is used to generate a protective immune response in a host, including humans, to a serine-threonine kinase (STK) of a strain of *Chlamydia*. A non-replicating vector, including a plasmid vector, contains a nucleotide sequence encoding an STK or a fragment of the STK that generates antibodies that specifically react with STK and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the STK in the host. The non-replicating vector may be formulated with a pharmaceutically-acceptable carrier for *in vivo* administration to the host.

